| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.34B | +5.3% |
| Gross profit | ¥0.15B | — |
| Operating income | ¥0.08B | — |
| Net income | ¥0.07B | -18.2% |
| Gross margin | 43.5% | Net margin 19.1% |
| Revenue Q/Q | +51.0% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.19B | 56.5% |
| R&D | ¥0.02B | 5.1% |
| SG&A | ¥0.05B | 13.8% |
| Tax & other | ¥0.01B | 3.1% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
华仁药业 ・ 向日葵 ・ 万讯自控 ・ 顺网科技 ・ 长盈精密 ・ 东方日升 ・ 瑞普生物 ・ 经纬辉开 ・ 阳谷华泰 ・ ST亚光 ・ *ST聆达 ・ 锐奇股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies